MOLOGEN AG
MOLOGEN AG: first half of 2015 defined by study progress and capital increase (news with additional features)
MOLOGEN AG / Key word(s): Half Year Results PRESS RELEASE N 13 / 2015 of 08/13/2015 MOLOGEN AG: first half of 2015 defined by study progress and capital increase – Progress in the colorectal and lung cancer study; partner starts HIV study with lead product MGN1703 – Cash inflow of EUR 28.3 million following capital increase – Forecast for 2015 financial year confirmed – Dr. Mariola Söhngen appointed as new Chief Executive Officer (CEO); further changes in Executive Board – Oliver Krautscheid re-elected as member and Chairman of the Supervisory Board Berlin, August 13, 2015 – In the first half of 2015, the operating activities of the biotech company MOLOGEN AG essentially focused on the study program with the lead product, immunotherapy MGN1703. Patient enrollment for the pivotal IMPALA study (colorectal cancer) and the phase II IMPULSE study (small cell lung cancer) continued in line with expectations. Furthermore, the Danish Aarhus University Hospital started the cooperative study with a phase I TEACH clinical trial for the treatment of HIV (Human Immunodeficiency Virus) in June 2015. The company received gross proceeds of EUR 28.3 million through a capital increase, which was successfully carried out in April 2015. The outlook for the 2015 financial year has been confirmed. Shortly after the end of the reporting period, MOLOGEN announced the appointment of Dr. Mariola Söhngen as the new Chief Executive Officer (CEO), with effect from November 1, 2015. At this year’s MOLOGEN Annual General Meeting, Oliver Krautscheid was re-elected as a member of the Supervisory Board. Progress was made in the enrollment of patients for studies with lead product MGN1703 The phase II IMPULSE study with MGN1703 in the indication small cell lung cancer intends to enroll 100 patients across four European countries. The recruitment phase is expected to be completed still this year. Dr. Matthias Schroff, Chief Executive Officer (CEO) of MOLOGEN AG: “We are making good progress with patient recruitment, not least because of the excellent support from the investigators involved. We are expecting to conclude recruitment within the scheduled time frame.” As part of a cooperation with MOLOGEN, the Danish Aarhus University Hospital has started patient recruitment for an early-phase TEACH study to test the immunotherapy MGN1703 in HIV patients. It has received funding for this purpose from the American Foundation for AIDS research (amfAR). MOLOGEN is providing the investigational medicinal product MGN1703 for the trial. In the first half of 2015, the company again presented research and development results at major international scientific conferences. At the start of June 2015, updated data on the concluded colorectal cancer IMPACT study was presented at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA. Capital increase secures funding for research programs up to end of 2016 at least R&D expenditure to shape EBIT development New Chief Executive Officer from November 1, 2015 and re-election of Oliver Krautscheid as member and Chairman of the Supervisory Board This year’s Annual General Meeting in Berlin on July 29, 2015 re-elected Oliver Krautscheid to the Supervisory Board. In addition, the Supervisory Board once again elected Oliver Krautscheid as Chairman of the Supervisory Board. The complete report of MOLOGEN AG for the first half of 2015 is available at the company’s website www.mologen.com. MOLOGEN AG The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and strong activation of the immune system. Due to this mechanism of action, MGN1703 has the potential to be applied to various indications. MGN1703 is currently being developed for first-line maintenance treatment of colorectal cancer (pivotal study) and small cell lung cancer (randomized controlled trial). Furthermore it is also being investigated in a phase I study in HIV. MOLOGEN’s pipeline focus is on new innovative immunotherapies to treat diseases for which there is a high medical need. MOLOGEN AG is listed on the stock exchange and its headquarters are located in Berlin, Germany. The shares of the company are listed on the Prime Standard at the Frankfurt Stock Exchange (ISIN DE0006637200). www.mologen.com MIDGE(R), dSLIM(R), EnanDIM(R) and MOLOGEN(R) are registered trademarks of MOLOGEN AG. Contact Note about risk for future predictions
+++++ Additional features: Document: http://n.equitystory.com/c/fncls.ssp?u=THFDUDFLNV Document title: MOLOGEN AG: first half of 2015 defined by study progress and capital increase 2015-08-13 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
Language: | English | |
Company: | MOLOGEN AG | |
Fabeckstraße 30 | ||
14195 Berlin | ||
Germany | ||
Phone: | 030 / 841788-0 | |
Fax: | 030 / 841788-50 | |
E-mail: | presse@mologen.com | |
Internet: | www.mologen.com | |
ISIN: | DE0006637200 | |
WKN: | 663720 | |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart | |
End of News | DGAP News-Service |
386371 2015-08-13 |